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Abstract
Background: The prognostic value of CD4 counts and RNA viral load for identifying treatment need in HIV-infected
individuals depends on (a) variation within and among individuals, and (b) relative risks of clinical progression per unit CD4
or RNA difference.
Methodology/Principal Findings: We reviewed these measurements across (a) 30 studies, and (b) 16 cohorts of untreated
seropositive adults. Median within-population interquartile ranges were 74,000 copies/mL for RNA with no significant
change during the course of infection; and 330 cells/mL for CD4, with a slight proportional increase over infection. Applying
measurement and physiological fluctuations observed on chronically infected patients, we estimate that 45% of population-
level variation in RNA, and 25% of variation in CD4, were due to within-patient fluctuations. Comparing a patient with RNA
at upper 75th centile with a patient at median RNA, 5-year relative risks were 1.4 (95% CI 1.2–1.7) for AIDS and 1.5 (1.3–1.9)
for death, without change over the course of infection. In contrast, for a patient with CD4 count at the lower 75th centile,
relative risks increased from 1.0 at seroconversion to maxima of 6.3 (4.4–8.9) for AIDS and 5.5 (2.7–10.1) for death by year 6,
when the population median had fallen to 300 cells/mL. Below 300 cells/mL, prognostic power did not increase, due to a
narrower CD4 range.
Conclusions: Findings support the current WHO recommendation (used with clinical criteria) to start antiretroviral
treatment in low-income settings at CD4 thresholds of 200–350 cells/mL, without pre-treatment RNA monitoring – while not
precluding earlier treatment based on clinical, socio-demographic or public health criteria.
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Introduction
CD4 cell counts (CD4) and RNA viral loads (RNA) are the two
most commonly used prognostic markers of the clinical progres-
sion of HIV infection [1–3]. In the chronic stage of infection, the
level of viral replication, as measured by the concentration of RNA
in the blood, largely determines the time from initial infection to
AIDS and death: high initial RNA is a marker for rapid
progression, and in all individuals clinical progression is preceded
by an increase in RNA [4–8]. As infection progresses, CD4
declines [9,10] and should, in principle, provide a measure of the
remaining time to AIDS and death. Despite a broad consensus on
these prognostic patterns, recent observations of poor correlation
between RNA and CD4 decline rates in adult patients have led to
a renewed debate over the relative merits of RNA and CD4 as
prognostic indicators in the absence [11,12] and presence [13] of
highly active antiretroviral treatment (ART).
As ART becomes increasingly available in low-income countries
[14], knowledge of the natural history of HIV infection and the
prognostic value of RNA and CD4 measurements is increasingly
important:
N On a population basis, to help determine at what threshold it is
most effective, and cost-effective, to begin therapy of
treatment-naı¨ve patients [15];
N On an individual basis, to refine management of treatment-
naı¨ve patients [15];
N To optimize treatment allocation among patients in settings
where available resources cannot (yet) meet the full demand for
ART [16];
N To improve the empirical basis for prognostic and epidemi-
ological models of the impact and cost-effectiveness of ART
[16].
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The prognostic value depends on (i) the relative risk of
progression per unit difference in RNA or CD4, and (ii) the
extent to which RNA and CD4 levels vary within populations.
The interpretation of published data on these two components of
prognostic value is complicated by several factors. First, prognostic
values are likely to vary as the infection progresses. Unfortunately,
in many studies dates of seroconversion are not known or known
only with considerable uncertainty. Further, among (and within)
studies with known dates of seroconversion, the timing of RNA or
CD4 ‘baseline’ measurements varies, as does the subsequent
duration of follow-up. Second, studies use a variety of outcome
measures and analytical methods to interpret observed associa-
tions.
To determine the comparative prognostic values of RNA and
CD4 over the course of untreated infection, we review and analyze
quantitative data on progression risks associated with high RNA
and low CD4, and within-population variability in both markers,
from high-quality cohort studies of HIV-seropositive adults. All
observations are ‘standardized’ in types of outcome measure, and
in time relative to the intervals since seroconversion of patients. As
a complementary approach, magnitudes of within-patient (labo-
ratory and physiological) and among-patient variation are
reviewed and compared between RNA and CD4. Results are
discussed in the light of treatment initiation recommendations and
CD4/RNA testing algorithms that are either in use or have been
proposed for low-income settings.
Methods
Literature review
Studies on RNA, CD4 and their variation within HIV-1
infected populations, and the risks of AIDS and death
associated with high RNA or low CD4 published up to May
2008 were identified by PubMed search. Search terms included
(HIV-1 OR AIDS), (RNA OR viral load), CD4, (longitudinal
OR cohort OR seroconver* OR prognos*), and (AIDS OR
mortality OR survival OR progress* OR (natural history)).
Relevant publications (in English, French or Spanish) were
traced backward and forward in time to identify additional
data on the same patient cohort. In instances needed, authors
were contacted to obtain or verify data from eligible studies.
Study selection and analyses adhered to the MOOSE Guidelines
for Meta-Analyses and Systematic Reviews of Observational Studies (see
Text S1) [17].
Outcome measures considered were:
N Relative risks associated with high RNA or low CD4 for
subsequent development of clinical AIDS and/or death.
N RNA and CD4 median or mean levels, with interquartile
ranges (IQRs) or other centiles (e.g. 10th and 90th), minimum,
maximum and standard deviations (SD).
Studies were included if:
N They reported one or more relevant outcome measures for
HIV-1 seropositive adults aged$15 years. All types of risk
population, including men having sex with men, injection drug
users, haemophiliacs, and heterosexually infected men and
women, were eligible, as well as all types of study samples
including general population surveys, clinic or hospital patient
reports, sero-incident cohorts and sero-prevalent surveys.
However, study groups were not allowed to have been selected
according to their subsequent prognosis or the presence or
absence of symptoms during primary infection.
N They reported the average duration of infection in the study
population at time of the relevant ‘baseline’ RNA or CD4
measurement, based on (estimated) patient seroconversion
dates from serotesting at regular intervals.
N Quantification of RNA was done using a Reverse Transcrip-
tase-Polymerase Chain Reaction assay, with a lower detection
limit of less than 1000 copies/mL. Both serum and plasma
measurements were included, as these differ only by a
relatively small amount compared to variations over time
and between individuals [18,19].
N For prognostic studies, median follow-up was more than 1
year.
N Study subjects were not treated with triple-therapy ART or
any antiretroviral combination containing protease inhibitors.
Studies that included patients receiving zidovudine monother-
apy or two nucleoside analogues (for subgroups of participants,
during part of follow-up) were included, because these
regimens do not significantly affect RNA or CD4 levels over
several years [5,8], which was the typical length of follow-up in
prognostic studies analyzed – and two studies reported no
influence of non-triple ART use on RNA and CD4 prognostic
value [20,21].
Within-population variability in RNA and CD4
For within-population variability in RNA and CD4 levels,
eligible studies had to report at least two statistics of: median,
mean, IQR or other centiles, minimum, maximum and standard
deviation. We standardized variability statistics across all studies as
medians with IQRs, deriving missing medians and IQRs by
applying normal distributions on transformations of the reported
alternative statistics.
Appropriate transformation functions that normalized RNA
and CD4 distributions were identified by analysis of raw data from
a cross-sectional survey of HIV-infected South-African men [22].
A Box-Cox transformation [23], that minimizes the skewness of
the frequency distribution, was found to produce adequate normal
distributions:
y~ xl{1
 
l
where x is the untransformed value of RNA viral load (copies/mL)
or CD4 (cells/mL) and y is the corresponding transformed value.
Estimated values of l that fitted the South African data were
0.1606 for RNA and 0.5420 for CD4. The same power law and
values of l were then used to derive RNA and CD4 medians and
IQRs from studies not reporting these statistics, by fitting
cumulative distribution functions [24].
Relative prognostic risks associated with RNA and CD4
The analysis of relative risks associated with high RNA and low
CD4 focused on the two outcome measures AIDS and death.
Standard definitions of AIDS (group C of the Centers for Disease
Control and Prevention 1993 [25] or 1986/7 [26], or European
1993 [27] classification) were accepted. Where available, we
included the reported univariate relative risks per 100 cells/mL
lower baseline CD4, and per 10-fold (1 log10/mL) higher baseline
RNA. Univariate risks were felt to best reflect the value of simple,
individual predictor variables as used in clinical practice (where
e.g. CD4 thresholds are constant irrespective of patients’ RNA,
age and sex). For studies reporting only multivariate risks (adjusted
for covariates), however, those measures were included.
HIV Progression and CD4/RNA
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To capture the maximum possible information from relevant
studies despite limitations in data and variability in risk measures
reported (Table 1), we proceeded as follows:
N Studies which reported relative risks only for quartiles of RNA
or CD4 were included, assuming that each successive quartile
approximated a 10-fold higher RNA or a 100 cells/mL lower
CD4 – as was the case in one study that reported on both risk
measure units [21].
N Where progression risk was reported as ‘non-significant’
without specification of the exact value, this was entered as 1.0.
N From studies that reported relative risks for RNA or CD4
‘baseline’ measurements taken at two or more different
timepoints relative to seroconversion [4,28,29], all estimates
were included, to capture all information on the development
over time in the prognostic marker.
N From studies that reported risks over two or more different
durations of follow-up (from a fixed timepoint of baseline RNA
or CD4 measurement) [30,31], we included the estimate for
the shortest follow-up duration, as short-term prognostic
indications are likely to be most relevant in patient
management.
N For studies of seroprevalent cohorts for whom no (estimated)
median time interval between seroconversion and (baseline)
RNA or CD4 measurement was reported, this timepoint was
imputed based on the reported baseline CD4 level and the
relationship between the measurement timepoint and baseline
CD4 in studies that reported both.
The dependence of risks on timepoint of RNA/CD4 measure-
ment, duration of follow-up, average rate of progression to AIDS
or death during follow-up, median baseline CD4 in the study
population, geographical region and use versus non-use of
antiretroviral mono- or bi-therapy at baseline and during follow-
up was assessed in linear regression. All studies were weighted
equally, because heterogeneity in risks due to factors such as study
design and follow-up, setting, clinical spectrum of patients at
baseline and median progression rates was much greater than
sampling errors. Factors significant at p,0.10 in univariate
analysis were considered for multivariate models.
Components of within-population variability
As a complementary indication of the population-level prog-
nostic values of RNA and CD4 measurement, we quantified the
extent to which within-population variation in each measure
reflects within-individual variation, due to laboratory measure-
ment error and/or short-term physiological fluctuation – which
confounds prognostic value – versus variation among individuals –
which determines and constitutes clinical prognostic value.
Relevant studies reporting components of within-individual
variability for both RNA and CD4 from the same set of patients
were identified by searching PubMed. Their results were analyzed
in the light of total within-population variations aggregated from
the larger set of studies reporting the latter.
Results
Within-population variability in RNA and CD4
RNA medians with IQRs at a specified (estimated) time after
seroconversion were available from 57 measurements (Figure 1a).
Across these data, population medians varied widely, between
5,000 and 390,000 copies/mL. The IQR averaged around
74,000 copies/mL, or 2.5 times the population median. For the
overall median across studies of 28,000 copies/mL the corre-
sponding IQR would be <8,000–82,000. In linear regression, the
IQR did not change significantly with the timepoint after
seroconversion (p = 0.37), but increased with increasing population
median RNA (p,0.001). When expressed as a proportion of
population median value, the IQR did not vary with time
(p = 0.64) or with median RNA value (p = 0.052).
For CD4, across 51 datapoints, population medians decreased
over time after seroconversion, from around 600 cells/mL in the
first year to 360 cells/mL for populations sampled at around 8
years after seroconversion (Figure 1b; p for trend,0.001).
Corresponding IQRs averaged 330 cells/mL, or 0.65-fold the
population median. For the overall median of 500 cells/mL the
corresponding IQR would be 360–700 cells/mL. In linear
regression, the IQR did not vary significantly with either the
population-specific median CD4 or the timepoint after serocon-
version (p = 0.11 and 0.095, respectively). When expressed as a
proportion of population median, however, the IQR increased
with time after seroconversion (p,0.001; Figure 1b).
Relative prognostic risks per unit RNA or CD4 difference
Mean relative risks per 10-fold higher RNA were 2.0 (95%
confidence interval (CI): 1.8–2.5) for AIDS (12 studies, 17
datapoints) and 2.5 (2.1–3.0) for death (9 studies, 10 datapoints;
Table 1). These prognostic risks did not vary over time after
seroconversion (Figure 2a and 1b), or with duration of follow-up,
geographical region, baseline CD4, use of antiretroviral mono-/bi-
therapy, or average clinical progression rates (see Text S2).
In contrast, relative risks per 100 cells/mL lower CD4 increased
with time after seroconversion, for both AIDS (10 studies, 14
datapoints) and death (7 studies, 8 datapoints; Table 1) (Figures 2c
and 1d): from 1.0 at seroconversion to an estimated 3.0 (95% CI
2.6–3.4) by 6 years for AIDS (p,0.0001 for trend), and to 2.8
(1.9–3.7) for death (p,0.0001). In multivariate regression, this
pattern was not modified by duration of follow-up, geographical
region, baseline CD4, use of antiretroviral mono-/bi-therapy or
average progression rates (see Text S2).
Prognostic power at population level
When combining the results from Figures 1 and 2, population-
level prognostic powers can be approximated as the relative risk
for a hypothetical patient with RNA at the upper 75th centile or
CD4 at the lower 75th centile, compared to a patient with exactly
the median RNA or CD4 level in a given population (Figure 3).
Whereas relative risks per 10-fold RNA (multiplicative) increase
were similar to relative risks per 100 cells/mL (linear) CD4 decline
(Figure 2), the population-level prognostic value was then
considerably higher for CD4 than for RNA, except for populations
limited to very recently infected people. For RNA, relative
prognostic risks for a patient with viral load at upper 75th centile
were a modest 1.4 (95% CI 1.2–1.7) for AIDS and 1.5 (95% CI
1.3–1.9) for death, compared to a patient with median RNA.
These values were constant across the range of population baseline
CD4 medians (Figure 3a).
For CD4, in contrast, the prognostic risk at the lower 75th
centile compared to the ‘median’ patient, rose markedly with
decreasing median CD4: from 1.0 (i.e., no prognostic information)
at CD4s above 625/mL – which, in our dataset, corresponded to
the time of seroconversion – to maxima of 6.3 (95% CI 4.4–8.9)
for AIDS and 5.5 (95% CI 2.7–10.1) for death in populations with
median 300 CD4/mL – which, in the dataset of prognostic risks,
corresponded to around 6 years after seroconversion (Figure 3b).
The time pattern of increasing CD4 prognostic risks was
stronger at a population level (Figure 3b) than at individual-level
(Figure 2c&d), because the (proportional) population-level vari-
HIV Progression and CD4/RNA
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ability in CD4 increases over time after infection (Figure 1b).
Below a population median of 300 cells/mL (around year 6 after
seroconversion), the absolute CD4 range within populations
started to decrease (despite continued increase in proportional
variability). As a result, population-level prognostic value tended to
fall again, although this decline did not reach statistical
significance within the CD4 range evaluated (down to 190 cells/
mL; Figure 3b). In intuitive terms: by the time that most or all
patients have progressed to low CD4, the prognostic value of CD4
will start to decrease.
Components of within-population variability
One study reported components of within-population variability
for plasma RNA and CD4 simultaneously [32], permitting a
comparison of variability components between the indicators. In
this study, 30 clinically stable seropositive men in the UK receiving
antiretroviral mono-therapy had blood samples taken for RNA
and CD4 measurement at 6 occasions spread over 6 months. Each
sample was analyzed twice. Differences between duplicate assays
were considered to reflect laboratory/measurement error, while
variation between visits within a patient was attributed to
physiological fluctuation.
For RNA, among patients with enrollment levels of .500/mL,
the median within-patient range of values across 6 measurements
was <6,500 copies/mL (0.76 log10), while the median difference
between duplicate assays was <1,500/mL (0.2 log10). For CD4,
the median within-patient range over 6 months was 119 cells/mL,
and the median difference between duplicate assays 16 cells/mL.
Using components of variance analysis, the authors estimated that
for RNA, physiological and measurement factors accounted for
55% and 45% of variation within individuals, while corresponding
contributions were 92% and 8% for CD4 [32].
Figure 4 shows how this within-individual variability contributes
and compares to overall within-population variability. Outcomes
for all three variability components (among individuals in a
population, within-individual physiological and within-individual
laboratory measurement error) were standardized as ‘coefficients
of variability’, relative to the corresponding population median
values (Table 2). For RNA, total within-individual variation was
thus estimated to make up about 45% of within-population
variation. For CD4, within-individual variation would account for
around 25% of within-population variation. The corresponding
estimated proportion of variation among individuals is therefore
smaller for RNA than for CD4 (55% and 75%, respectively: blue
areas in Figure 4), reinforcing the conclusion that, among patients
in the chronic stage, CD4 has better prognostic power than RNA.
Discussion
This quantitative review confirmed that RNA and CD4 have
very different time patterns of clinical prognostic value during
untreated HIV-1 infection [4].
Within the first 2 years of infection, RNA immediately gives
some indication of long-term prognosis. Due to constant relative
risks (Figure 2a&b) and constant within-population variability
(Figure 1a), RNA remains similarly informative when measured
during later years (Figure 3a). CD4, in contrast, carries little
prognostic value over early years. Its within-population variability
then instead largely relates to pre-infection CD4 levels, which vary
by up to a factor ten among uninfected adults without influencing
prognosis after infection [10]. As infection progresses and
worsening immune deficiency allows opportunistic infections
(OI) and AIDS-defining illnesses to occur, the prognostic value
of CD4 increases (Figure 3b), due to strong increases in relative
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prognostic risks per unit CD4 decrease (Figure 2c&d) and
increasing proportional within-population variability in CD4
levels (Figure 1b). Part of the prognostic value may reflect that
OI themselves temporarily reduce CD4 [33] and increase RNA
[34,35] 2 effects that may be common in clinic populations where
the occurrence of OIs is often the reason for diagnosis, especially
in Africa. The pattern of diminishing CD4-related progression
risks at higher baseline CD4 (Figure 2c+d) was also observed in a
recent multi-center analysis of patients starting immediate versus
deferred ART [36]: Here, the prognostic value of CD4 2 as
measured by AIDS/death risks associated with deferring ART 2
was high at low CD4 thresholds, but marginal at thresholds in the
range of 500 cells/mL.
Within 2 years after seroconversion, CD4 surpasses RNA as a
prognostic marker, and in later years its prognostic value far
exceeds that of RNA (Figure 3). This estimation supports the
natural history model whereby viral replication drives CD4 decline
and clinical progression (Figure 5a). The marked superiority of
CD4 as prognostic marker during untreated infection is further-
more supported by its estimated near 2-fold smaller proportional
laboratory measurement error and physiological fluctuation within
patients, compared to RNA (Figure 4).
Implications for ART initiation and allocation
As of 2008, the common protocol in USA and Western Europe
is to initiate treatment when CD4 falls below 350/mL or in case of
a history of an AIDS-defining illness [1]. For low-income
countries, as a ‘public health approach’ the WHO recommends
ART for people in WHO clinical stage IV regardless of CD4,
consideration of treatment in stage III with CD4 below 350/mL,
and treatment for those with CD4 below 200/mL regardless of
clinical stage [3]; determining viral load is unnecessary. Our
results support the WHO recommendation to start antiretroviral
treatment in low-income settings based on clinical criteria
supplemented with CD4, without pre-treatment RNA monitoring
2 if the purpose of ART is to maximize clinical benefit among
patients for given treatment and diagnostic inputs. By revealing
that prognostic power is highest in populations with median CD4
around 300/mL (Figure 3b), findings furthermore assist in
interpreting recommendations for how to manage treatment-naı¨ve
Figure 1. (A) RNA viral load; (B) CD4 cell counts, over the course of untreated HIV-1 infection in adults. Each blue dot represents one datapoint of a
median RNA or CD4, with the horizontal error bar indicating the corresponding interquartile range in the study population. Bold pink lines are
medians across all population medians, for which thin pink lines indicate the corresponding interquartile range. Data sources: (a) [6–8,11,28,29,31,66–
85]; (b) [7,8,11,28,29,31,66–71,73–88]. The (linear) trends over time since seroconversion in population median RNA and CD4 should not be
interpreted as a proxy of trends in RNA and CD4 in individual patients. Since population medians are conditional on patients being alive, in individual
patients RNA will instead tend to increase over time, and CD4 will tend to decrease stronger than apparent from Figure 1b.
doi:10.1371/journal.pone.0005950.g001
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individuals with CD4 between 200–350/mL 2 an area of
therapeutic uncertainty.
Simulation studies that combined assumed CD4 and RNA
prognostic risks and within-population variabilities with observed
clinical responses to ART in different CD4 and RNA strata also
found that application of CD4 thresholds to supplement clinical
criteria improves the effectiveness and cost-effectiveness of ART
[37–39]. An observational study of South African patients added the
proviso that clinical criteria alone are a better predictor of disease
progression and ART benefit than CD4 alone [40]. Studies
evaluating different CD4 thresholds predicted that thresholds above
350 cells/mL would save more lives and life-years, but at lesser cost-
effectiveness [38,41] 2 with routine start at CD4,350/mL being
cost-effective by international economic standards [42].
Regarding the utility of RNA measurement, two models
comparing CD4-based and RNA-based treatment initiation con-
cluded that, to scale-up ART beyond symptomatic patients
presenting in clinics, combined RNA/CD4 algorithms would be
most efficient [43,44]. In contrast, a comparison of clinical, CD4- and
RNA-based screening algorithms for a population in Coˆte d’Ivoire
found RNA testing to be of high cost and dubious additional benefit
[45], and another simulation predicted low cost-effectiveness for
adding RNA measurement to clinical criteria and CD4 testing [39].
Most simulation models assumed a fixed increase in risk of
clinical progression per unit CD4 decline during untreated
infection, throughout the spectrum of CD4 levels and infection
stages. This simplistic assumption is at odds with the progressive
increase in relative hazard with decreasing CD4 stratum (i.e.
increasing duration of infection) that emerged from our analysis
(Figure 2c&d). Furthermore, only one model [38] incorporated
random fluctuation in CD4 (or RNA) measurement in
simulations. If accounting for both the time-changing CD4-
related risk and dilution of prognostic value due to within-
individual fluctuations that our analyses quantified, these models
would probably predict an even lower cost-effectiveness for
applying CD4 thresholds above 350 cells/mL and for RNA pre-
treatment monitoring.
Implications for screening strategies for ART-naı¨ve
people
The substantial within-patient fluctuation for both CD4 and
RNA implies that prognostic value can be improved by repeating
blood sampling and measurements within patients, and evaluating
their average levels over time. Pooling repeat values would probably
increase prognostic risks relative to those shown in Figures 2&3,
which mostly derived from single RNA or CD4 measurements.
Modelling studies have calculated, as the most efficient CD4
testing algorithm for ART-naı¨ve people, a default measurement
frequency of not more than once yearly [44], with repeat
testing for patients whose initial value is close above the
treatment threshold (e.g. between 350–400 cells/mL) [38,41].
Stratification by age, with more frequent tests for older people
in whom CD4 declines faster, would further increase efficiency
[38,41].
Figure 2. Relative risks of clinical HIV progression per unit difference in RNA or CD4. A. Risk of AIDS per 10-fold (1 log10/mL) higher RNA;
B. Risk of death per 10-fold (1 log10/mL) higher RNA; C. Risk of AIDS per 100 cells/mL lower CD4; D. Risk of death per 100 cells/mL lower CD4. Each
symbol represents the estimate from 1 study, of a population of HIV-1 infected adults (see Table 1 for details of studies). Risks are displayed as a
function of the median time since HIV seroconversion that RNA or CD4 was first measured. Horizontal error bars indicate the median duration of
follow-up over which RR was evaluated. Dashed lines in (a) and (b) indicate pooled median RRs across studies, which did not vary with time since
seroconversion. Dashed lines in (c) and (d) indicate linear trends of increasing RR with stage that CD4 was measured (from a defined value of 1.0 at
seroconversion; c: Pearson’s R2 = 0.74; p,0.0001; d: Pearson’s R2 = 0.89; p,0.0001). Median follow-up across studies and datapoints were (a) 4.8 years;
(b) 6.3 years; (c) 4.9 years, (d) 4.6 years. If instead of univariate relative risks, multivariate relative risks were preferentially included from studies that
reported both, results did essentially not change (a: 6 studies reporting both RRs, with median ratio of multivariate-to-univariate RR 0.82; b: 6 studies
reporting both, median ratio of multivariate-to-univariate RR 0.84; c: 4 studies reporting both, median ratio of multivariate-to-univariate RR 0.94; d: 5
studies reporting both, median ratio of multivariate-to-univariate RR 0.91).
doi:10.1371/journal.pone.0005950.g002
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Limitations
The analyses have several limitations. First, the majority
(,75%) of eligible studies were from high-income, Western
settings – leaving the applicability of findings uncertain especially
in Africa.
For relative risk studies, data analyzed were limited to untreated
cohorts and did not address toxicity, viral resistance and cost
associated with (early versus late) ART. We nevertheless believe
that the findings are important for clinical decision making,
because the prior question that physicians face is their patients’
prognosis if treatment is not initiated. Furthermore, despite our
attempts to include only high-quality studies and to focus on
standardized outcomes with known covariates, our pooled analyses
are not meta-analyses in the strict sense. Notably, included studies
varied in rates of loss to follow-up, extent of exposure to
antiretroviral mono- or bi-therapy, OI prophylaxis and treatment,
and patient inclusion criteria and age ranges; however, available
(cohort-aggregate, rather than individual-patient) data and
statistical power precluded optimal assessment of these possible
determinants (see Text S2).
Although one would ideally like to know absolute risks of AIDS
and death, these are both highly variable between patients and
uncertain. Therefore, treatment guidelines must be based on
population estimates of relative risks for different categories of
patients, such as we provide.
Analyses focused on RNA and CD4 as independent individual
markers, ignoring non-laboratory-based markers that are typically
more accessible, at lower cost, for larger groups of patients.
Notably, age at initial infection is an important determinant of
survival [46–48], which in part underlies the effect of RNA and
CD4: older patients have higher viral setpoints [49] and hence
faster CD4 decline and disease progression (Figure 5b). Since age
at initial infection or its approximation, ‘age at first clinical
presentation’, will be available for all patients even in the most
peripheral facilities, the most relevant question to answer would be
the prognostic value of RNA and CD4 additional to age (and clinical
and other socio-demographic factors) [47]. Published reports did
not allow such analysis, but this will be eagerly awaited from
multicentre patient cohorts such as CASCADE, ART-LINC and
ICONA [47,50,51].
When considering expansion of CD4-guided treatment initia-
tion, thresholds may furthermore need to be differentiated
between populations, to account for geographical and age/sex
differences in pre-infection distributions [10]. For example, in
Figure 3. Population-level prognostic power of RNA and CD4 in untreated HIV-1 infection. A. Relative prognostic risk (RR) for a typical
patient at 75th centile highest RNA, compared compared to the average patient with exactly the population-median RNA value; B. Relative
prognostic risk for a typical patient at 75th centile lowest CD4, compared compared to the average patient with exactly the population-median CD4
value. Results are expressed as a function of median CD4 in the population, for the range of median CD4 levels found in studies analyzed in Table 1
and Figure 1. CD4 population medians were calculated as a linear function of the median year after seroconversion, based on the studies presented in
Table 1. Bold lines indicate best estimates; thin lines 95% confidence intervals.
doi:10.1371/journal.pone.0005950.g003
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populations with low CD4 levels in both HIV-infected and HIV-
uninfected adults, such as Ethiopians [52] and Chinese [53],
thresholds above 350 cells/mL would probably be (even) less
efficient than in other populations.
In the analysis of within-population variabilities, we did not
attempt to explain variation among studies in median marker levels
beyond that explained by stage of infection (Figure 1). The wide
variation in population medians for both RNA and CD4 is itself a
significant observation, which may justify further investigations
into geographical and socio-demographic patterns – as well as
reflection on the validity of universal, international reference
values and treatment thresholds [10].
The analysis of components of within-population variability
in CD4 and RNA (Table 2 and Figure 4) was based on the
findings of just one 30-patient dataset [32]. No other studies
were identified that estimated the contributions of measure-
ment error and physiological fluctuation for both RNA and
CD4 in parallel. However, several studies that measured a
subset of these outcomes supported the findings of study [32],
namely:
N RNA measurements fluctuate within patients over short
periods of time by 0.2–0.5 log10 copies/mL [54–58], with
measurement error and physiological fluctuation (without a
Figure 4. Within-population variability in RNA and CD4 during untreated adult HIV-1 infection, by component of variation.
‘Coefficients of variability’ were defined and calculated as described in Table 2. The percentages written in the blue bars indicate the proportion of
overall variability that is not attributable to within-patient factors.
doi:10.1371/journal.pone.0005950.g004
Table 2. Definition and calculation of components of within population-variability in RNA viral load and CD4 cell count during
untreated HIV-1 infection in adults.
Component of
variation Definition of ‘Coefficient of Variability’ Data sources Coefficient of variability (calculation)
RNA (copies/mL) CD4 (cells/mL)
Measurement error Median difference between duplicate assays within a
patient visit, as proportion of population median value
[32] 46% ( = 1,538/3,311*) 4% ( = 16/400)
Physiological
variation
Within-individual variation minus measurement error,
as proportion of population median value
[32] 126% ( = 173%–46%) 20% ( = 24%–4%)
} (total) Within-
INDIVIDUAL variation
Median 95% range of values within a patient obtained
over 6 visits, as proportion of population median value
[32] 173% ( = 5,717/3,311*) 24% ( = 98$/400)
Additional variation
among individuals
Within-population variation minus within-individual
variation, as proportion of population median value
Studies of
Figure 1+; [32]
210% ( = 383%–173%) 74% ( = 98%–24%)
} (total) Within-
POPULATION variation
Median within-population IQR divided by 0.675#, as
proportion of population median value
Studies of
Figure 1+
383% ( = (73,600/
0.675#)/28,200)
98% ( = (330/
0.675#)/500)
*Samples with RNA.500 copies/mL only. The 95% confidence interval was calculated based on the reported standard deviation among 6 visits, of 0.264 log10 copies/
mL, applying a Student T-statistic for 5 degrees of freedom.
$Lacking a reported standard deviation, the 95% confidence interval was estimated by multiplying the reported full ( = 119 cells/mL) CD4 range among 6 visits with the
ratio of 95% range to full range ( = 5,392/6,563 copies/mL) in RNA.
#For a normal distribution, the 95% confidence interval is equal to the interquartile range divided by 0.675. As population median value, we here take the median
across all studies shown in Figure 2.
+Average within-population variability was taken from the pool of eligible studies depicted in Figure 1, as the sample in [32] was too small to provide a representative
estimate of typical within-population variability.
doi:10.1371/journal.pone.0005950.t002
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diurnal pattern) each contributing about half to this variation
[54,55,58–60];
N CD4 measures vary within patients by 60–130 cells/mL within
weeks, with a larger contribution of physiological (diurnal)
fluctuation than of measurement error [56,61,62];
N Proportionally, measurement error and overall within-individ-
ual variation are larger at lower median CD4 [56] and RNA
[32,63];
N During stable infection, overall within-subject variation is
proportionally larger for RNA than for CD4 [57].
While these analyses help to better understand the respective
value of RNA and CD4 measurements in decision making for
treatment-naı¨ve patients, biomarker testing and treatment alloca-
tion policies should ultimately reflect not just knowledge of HIV
natural history and clinical prognosis, but a broader societal
debate about the individual-level and public health objectives of
ART [16]. By end-2007, in low- and middle-income countries an
estimated 31% (2.9 out of 9.7 million) of people in need were
getting ART [14]. As long as resources remain insufficient to treat
all people in need, prioritization among patients must inevitably
consider not only the individual patient’s health gain, but also the
broader public health objectives: Is treatment meant to maximize
patients’ survival (for given treatment and diagnostic inputs)? To
restore workforce capacity, and/or to prevent orphaning and
reduce socio-demographic impact of HIV/AIDS? To contribute
to HIV prevention, by lowering viral load and reducing
transmission to sexual partners of patients? Different objectives
would guide treatment priorities in different directions: for
example to the sickest and oldest, to employees in critical
economic sectors and young parents [64], or to the most sexually
active (risk) groups and/or patients with highest RNA [65].
Conclusions
Although high RNA is the earliest predictor of clinical
progression after HIV seroconversion, for populations of treat-
ment-naı¨ve patients during stable infection or with unknown date
of seroconversion, CD4 surpasses RNA as a prognostic indicator
and screening tool to select patients in need of ART. The
prognostic value of CD4 in treatment-naı¨ve patients was shown to
be greatest in populations with median <300 cells/mL. Findings
support the WHO recommendation to start antiretroviral
treatment in low-income settings based on clinical criteria
supplemented with CD4, without pre-treatment RNA monitoring.
Whereas expanding CD4 treatment initiation thresholds to above
around 350 cells/mL would increase the life-years gained with
ART, the added value of CD4 measurement then diminishes. A
public health approach to expanding ART allocation in low-
income countries may benefit from differentiating or supplement-
ing CD4 thresholds by independent socio-demographic or public
health prognostic indicators, such as age.
Supporting Information
Text S1 MOOSE Guidelines for meta-analysis and systematic
reviews of observational studies – with specification of adherence of
literature searches, study selection and analyses conducted.
Found at: doi:10.1371/journal.pone.0005950.s001 (0.14 MB
DOC)
Text S2 Statistical Appendix. Univariate and multivariate
regressions of relative risks of clinical HIV progression associated
with higher RNA viral load and lower CD4 cell count.
Found at: doi:10.1371/journal.pone.0005950.s002 (0.08 MB
DOC)
Figure 5. Schematic natural history model of HIV-1 replication driving rates of CD4 decline and clinical progression. A. Survival varies
among individuals according to the level of viral replication – which is indicated by RNA after reach of the setpoint in the first months after
seroconversion: patients with highest RNA (red lines) have shortest survival; patients with lowest RNA (green lines) have longest survival. Rates of CD4
decline varies according to (1) RNA setpoint; and (2) pre-infection CD4, which varies independently without influencing prognosis upon infection.
Individuals with high CD4 before infection have faster subsequent CD4 decline (bold lines) than individuals with low pre-infection CD4 (dashed lines)
– for a given RNA and duration of survival. This natural history model has earlier been proposed based on data of cohorts of homosexual men in New
York city and Washington DC [89]. B. Refinement of natural history model to incorporate prognostic determinants not (or not entirely) operating
through RNA and CD4; these increase the within-population variability in survival (x-axis range). ‘Age’ here could symbolically be taken to also stand
for other factors independently associated with prognosis: e.g. good immune constitution at baseline or low exposure to pathogens causing
opportunistic infections, instead of young age.
doi:10.1371/journal.pone.0005950.g005
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